张文宏，最新发声

Core Viewpoint - The article emphasizes that China's biopharmaceutical industry is recognized as a "new pillar industry" at the national level, with significant global influence and innovative drug development, but raises concerns about the early sale of promising drugs to foreign companies instead of retaining them for domestic use [3][4]. Group 1: Industry Insights - In 2025, the transaction value for China's innovative drug licensing agreements is expected to exceed $130 billion, with over a hundred transactions reported [3]. - The example of BioNTech acquiring a drug from a Chinese company for under $1 billion and reselling it for over $10 billion highlights the lucrative nature of these transactions [3]. - The pricing issue for innovative drugs in China is a major concern, as seen with the significant price drop of Hengrui Medicine's PD-1 drug, which fell from 4.52 billion yuan in 2020 to under 2 billion yuan by 2024 [5]. Group 2: Recommendations for Improvement - Suggestions include improving the cost compensation mechanism for innovative drug usage and establishing a multi-faceted payment system involving both medical insurance and commercial insurance [6]. - There is a call for reforms in pricing and assessment mechanisms to allow for some degree of autonomous pricing for negotiated drugs [6]. - The need for a collaborative development approach among medical services, insurance, and pharmaceuticals is emphasized to ensure the sustainability of the healthcare system and the profitability of innovative drugs [4][6].